FUTONG TECH (00465) announced its interim results, reporting a loss attributable to shareholders of 34.836 million yuan, an increase of 6.54% year-on-year.
Futong Technology (00465) announced its interim results for the six months ending June 30, 2026. The group achieved a revenue of 43.653 million yuan, representing a year-on-year decrease of 25.1%; the loss attributable to shareholders amounted to 34.836 million yuan, an increase of 6.54% year-on-year; the loss per share was 0.11 yuan.
FUTONG TECH (00465) announced its interim results for the six months ended June 30, 2026, reporting a revenue of RMB 43.653 million, a decrease of 25.1% year-on-year; the loss attributable to the company's owners amounted to RMB 34.836 million, an increase of 6.54% year-on-year; the loss per share was RMB 0.11.
As the transformation of enterprise-level clients in the Chinese market deepens in digital applications and the IT market continues to evolve, the Group is actively providing enterprise management services to its clients, including two major businesses: Cloud Intelligence and Data Intelligence. During the six months ended June 30, 2026 (the Period), the Group further focused on digital products and upgraded solutions driven by cloud computing and AI, while reducing traditional integration business, resulting in an overall revenue decline of approximately 25%.
Related Articles

Suzhou Novosense Microelectronics (02676) announced its interim results, with a net profit attributable to the parent company of approximately 67.5918 million yuan, marking a turnaround from a loss to profit compared to the same period last year.

TYK MEDICINES-B(02410): The National Medical Products Administration has conditionally approved the marketing application for Dihydroartemisinin Mesylate Tablets (TY-9591 Tablets).

ZHENRO SERVICES (06958): Wang Yi has been appointed as an executive director.
Suzhou Novosense Microelectronics (02676) announced its interim results, with a net profit attributable to the parent company of approximately 67.5918 million yuan, marking a turnaround from a loss to profit compared to the same period last year.

TYK MEDICINES-B(02410): The National Medical Products Administration has conditionally approved the marketing application for Dihydroartemisinin Mesylate Tablets (TY-9591 Tablets).

ZHENRO SERVICES (06958): Wang Yi has been appointed as an executive director.

RECOMMEND





